Thanks @mtom
The key for me here is the "Upside risk to our valuation", i.e. things that would push the PT beyond $5.80:
- Tasly deal
- Label extension for Ryoncil
- ARDS for US only; royalties only and no upfront or milestones from a potential deal for this indication
- +++
Also, we won't be short of news with the following short term catalysts:
- Ryoncil approval & launch
- Phase 2/3 trial for Remestemcel-L in COVID-19 patients
- LVAD Phase 3 trial
- Readouts and partnerships for CHF & CLBP
- BP forgotten COVID-19 with Temcell for Japan & Remestemcel-L for other countries
A very busy time for Mesoblast, alternative treatment options for patients and for SHs an extremely exciting time to sit back and enjoy the ride
WFH - he'd be constantly on the phone and video conferences
No wonder SI looked buggered in his last Video- but, it is a great problem to have
GLTASHs
Bell Potter Daily Pack 16 April 2020, page-13
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.000(0.00%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.50 | $1.45 | $1.723M | 1.166M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5710 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 32924 | 6 |
View Market Depth
| Last trade - 10.55am 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |